- Home
- CTNM vs BTCS Comparison
CTNM vs BTCS Comparison
Compare CTNM & BTCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTNM
- BTCS
- Stock Information
- Founded
- CTNM 2009
- BTCS 2008
- Country
- CTNM United States
- BTCS United States
- Employees
- CTNM N/A
- BTCS N/A
- Industry
- CTNM
- BTCS Finance: Consumer Services
- Sector
- CTNM
- BTCS Finance
- Exchange
- CTNM Nasdaq
- BTCS Nasdaq
- Market Cap
- CTNM 248.7M
- BTCS 218.2M
- IPO Year
- CTNM 2024
- BTCS N/A
- Fundamental
- Price
- CTNM $12.16
- BTCS $5.96
- Analyst Decision
- CTNM Strong Buy
- BTCS Strong Buy
- Analyst Count
- CTNM 5
- BTCS 1
- Target Price
- CTNM $22.20
- BTCS $7.00
- AVG Volume (30 Days)
- CTNM 194.4K
- BTCS 2.8M
- Earning Date
- CTNM 11-05-2025
- BTCS 11-12-2025
- Dividend Yield
- CTNM N/A
- BTCS 0.85%
- EPS Growth
- CTNM N/A
- BTCS N/A
- EPS
- CTNM N/A
- BTCS N/A
- Revenue
- CTNM N/A
- BTCS $7,522,073.00
- Revenue This Year
- CTNM N/A
- BTCS $160.41
- Revenue Next Year
- CTNM N/A
- BTCS $46.15
- P/E Ratio
- CTNM N/A
- BTCS N/A
- Revenue Growth
- CTNM N/A
- BTCS 354.52
- 52 Week Low
- CTNM $3.35
- BTCS $1.13
- 52 Week High
- CTNM $20.24
- BTCS $8.49
- Technical
- Relative Strength Index (RSI)
- CTNM 56.27
- BTCS 66.13
- Support Level
- CTNM $10.65
- BTCS $4.95
- Resistance Level
- CTNM $12.14
- BTCS $6.15
- Average True Range (ATR)
- CTNM 0.92
- BTCS 0.34
- MACD
- CTNM -0.21
- BTCS 0.11
- Stochastic Oscillator
- CTNM 34.98
- BTCS 78.81
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About BTCS BTCS Inc.
BTCS Inc. ("BTCS" or the "Company"), short for Blockchain Technology Consensus Solutions, is a U.S.-based Ethereum-first blockchain technology company committed to driving scalable revenue and ETH accumulation through its hallmark strategy, the DeFi/TradFi Accretion Flywheel, an integrated approach to capital formation and blockchain infrastructure. By combining decentralized finance ("DeFi") and traditional finance ("TradFi") mechanisms with its blockchain infrastructure operations, comprising NodeOps (staking) and Builder+ (block building), BTCS offers one of the most sophisticated opportunities for leveraged ETH exposure, driven by scalable revenue generation and a yield-focused ETH accumulation strategy. Discover how BTCS offers operational and financial leveraged exposure to Ethereum through the public markets at www.btcs.com.